In clinic, there was one IRF2BP2-RARA-positive APL patient induced to CR by sole ATRA, though most of cases accepted ATRA plus chemotherapy-based regimen, so this result demonstrated that IRF2BP2-RARA was one ATRA-sensitive RARA rearrangement [89]. This evidence concerns the gene IRF2BP2 and acute promyelocytic leukemia.